The Heart Failure (HF) and Cardiomyopathies Learning Pathway at ACC.23/WCC provides a comprehensive overview of the latest developments in the field of HF. Over the past year, numerous pharmacologic and device therapy breakthroughs have been made in treating patients with HF, including treatments for HF with preserved ejection fraction, hypertrophic cardiomyopathy, and cardiac amyloidosis. Experts will bring attendees up to speed on these developments and focus on the recently updated AHA/ACC/HFSA Guideline for the Management of Heart Failure.